6533b86ffe1ef96bd12ce8a2

RESEARCH PRODUCT

Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.

Antonio CanoCarlos EhermenegildoJuan J. TarínPilar J. Oviedo

subject

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyIsoprostaneNeutrophilsEstrogen receptormedicine.disease_causeAntioxidantschemistry.chemical_compoundTherapeutic indexInternal medicineMedicineHumansRaloxifenePeroxidaseF2-Isoprostanesbiologybusiness.industryObstetrics and GynecologyMiddle AgedAntiestrogenIsoprostanesPostmenopauseOxidative StressEndocrinologyReproductive MedicinechemistryCardiovascular DiseasesMyeloperoxidaseRaloxifene Hydrochloridebiology.proteinFemalebusinessOxidative stressBiomarkersmedicine.drug

description

We investigated the effect of a therapeutic dose of raloxifene on the plasma levels of myeloperoxidase and F2alpha-isoprostanes, two markers of oxidative stress recently described as reliable indicators of coronary heart disease. Contrary to changes described in the literature for estrogens (E), raloxifene did not modify the levels of either myeloproxidase or F2alpha-isoprostanes after 3 or 6 months of treatment.

yearjournalcountryeditionlanguage
2005-12-01Fertility and sterility
10.1016/j.fertnstert.2005.05.072https://pubmed.ncbi.nlm.nih.gov/16359994